Biomarin Pharmaceutical Dividends
| BMRN Stock | USD 80.91 1.26 1.53% |
As of the 28th of April 2024, Dividends Paid is likely to drop to about 9.3 M. In addition to that, Dividend Paid And Capex Coverage Ratio is likely to grow to -1.41. Biomarin Pharmaceutical's past performance could be the main factor of why investors trade Biomarin Pharmaceutical stock today. Investors should clearly understand every aspect of the Biomarin Pharmaceutical dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Biomarin Pharmaceutical's dividend schedule and payout information. Biomarin Pharmaceutical dividends can also provide a clue to the current valuation of Biomarin Pharmaceutical.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 17.3 M | 9.3 M | |
| Dividend Yield | 0.00 | 0.00 | |
| Dividend Payout Ratio | 0.00 | 0.00 | |
| Dividend Paid And Capex Coverage Ratio | (1.48) | (1.41) |
Biomarin |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Biomarin Pharmaceutical must own a stock before its ex-dividend date to receive its next dividend.
Biomarin Pharmaceutical Dividends Paid Over Time
Today, most investors in Biomarin Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomarin Pharmaceutical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Biomarin Pharmaceutical dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.722 | Earnings Share 1.06 | Revenue Per Share 13.12 | Quarterly Revenue Growth 0.088 | Return On Assets 0.0177 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.